Tumor-associated neoantigen peptide-MHC complex

The Tumor-associated neoantigen peptide-MHC complex is formed when tumor-specific mutated peptides (neoantigens)—arising from somatic mutations, gene fusions, insertions/deletions, or abnormal post-translational modifications—are processed by the proteasome and loaded onto MHC class I (or sometimes class II) molecules. These complexes are displayed on the surface of tumor cells and are not found in normal tissues, making them highly specific targets for immune recognition by T cells. Recognition of these complexes by T cell receptors can elicit a potent and tumor-specific cytotoxic immune response, forming the rationale behind neoantigen-based cancer immunotherapies such as personalized vaccines, adoptive T cell transfer, and combinatorial treatments with immune checkpoint blockers or oncolytic viruses. Identification of these targets involves high-throughput sequencing and computational prediction of MHC binding and T cell immunogenicity. Major therapeutic challenges include tumor heterogeneity, MHC loss, and accurately predicting which complexes are truly immunogenic and clinically relevant.

Other names

tumor-specific neoantigen-MHC complexneoantigen-MHC complextumor neoepitope-MHC complexTSA-MHC complexneoantigenic peptide-MHC complex

Induction of T cell-mediated cytotoxicity to eliminate tumor cells, Restoration or enhancement of tumor antigen presentation, Overcoming immune tolerance by presenting non-self, tumor-specific peptides on MHC